Schneider Electric Launches Global Pharmaceutical Initiative; New Management Team to Help Customers Maximize Productivity of Assets, People

Nov 06, 2001, 00:00 ET from Schneider Electric

    PALATINE, Ill., Nov. 6 /PRNewswire/ -- Electrical industry leader
 Square D / Schneider Electric has stepped up its support of the pharmaceutical
 industry with the appointment of an international management team with deep
 experience in the industry to oversee the company's global pharmaceutical
     Global Marketing Manager Stephen Larson and Global Sales Directors Mark
 Liston and Ian Job-Smith, who are based in the U.S. and Europe, respectively,
 have been named to the new posts.  They lead an international staff of
 professionals in delivering a wide variety of product applications and
 services to the pharmaceutical market, including engineered equipment
 packages, embedded intelligence devices, software applications and a diverse
 portfolio of engineering, analytical and diagnostic services.
     "Creating a team that coordinates our support of the pharmaceutical
 industry worldwide enables us to put Schneider Electric's considerable muscle
 to work helping customers maximize the productivity of their assets and
 people," said Larson, a former Schneider Global Strategic Account Manager.
     Mark Liston, who served as Global Strategic Account Manager for Merck,
 coordinated Schneider's support of Merck's domestic and international project
 activity for the past four years.  The relationship between the two companies
 has influenced a number of Schneider's strategic initiatives in recent years,
 including asset management, regulatory compliance and the development of
 intelligent motor control centers.
     "Our ability to leverage global resources to support customers seamlessly
 across traditional geographical and cultural boundaries has been a significant
 benefit to the pharmaceutical industry," Liston said.  He pointed to Schneider
 Electric's new competency center, which provides application and technical
 resources to pharmaceutical customers, as one example of Schneider's far-
 ranging initiatives in support of the industry.
     Among the many products and services now being developed by Schneider in
 conjunction with pharmaceutical customers are FDA certification services for
 equipment, electronic validation documentation for 21 CFR Part 11 regulatory
 compliance and factory automation systems that are both open and secure.
     Ian Job-Smith, who coordinates Schneider's resources for European-based
 pharmaceutical companies, also serves as Global Strategic Account Manager for
 Glaxo-SmithKline.  "Our value to pharmaceutical companies is Schneider's
 ability to consistently provide a compliant solution, no matter where their
 facilities are located in the world," said Job-Smith.  "This consistent global
 solution helps pharmaceutical customers reduce the cost of constructing and
 managing their facilities."
     Job-Smith has been involved with the pharmaceutical industry for the past
 eight years.  In addition to his experience with Glaxo-SmithKline, he has
 worked with Astra-Zeneca and Novartis.
     For more information about Schneider Electric solutions for the
 pharmaceutical industry, call 1-800-392-8781, visit or or e-mail
     Schneider Electric, the World's Power and Control Specialist, provides
 electrical distribution, industrial control and automation products, systems
 and services to customers in the energy, buildings, industrial and
 infrastructure markets.  With leading international brands such as MERLIN
 67,000 employees generated sales of approximately 9.7 billion Euro in 2000
 through 9,000 sales outlets in 130 countries.
     CONTACT:  Jeanne Schweder of pricemcnabb, +1-704-916-6173, or, for Schneider Electric
                      MAKE YOUR OPINION COUNT - Click Here

SOURCE Schneider Electric